JAVELIN Bladder 100 Trial
Interviews with Experts at Conferences
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos
April 23, 2021
November 17, 2020
November 16, 2020
October 14, 2020
Conference Coverage
Conference Highlights from Recent Conference Coverage
Petros Grivas, MD, PhD
In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial. Read More
Yohann Loriot, MD, PhD
Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 trial. Read More